Project Grant K01AI185258
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$135K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94110, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $201,549 study focused on understanding the metabolic profiles and outcomes of tuberculosis (TB) patients in Tanzania. The key goals of the study are to: 1) measure and characterize a range of metabolic markers and TB severity at the time of TB diagnosis, and 2) evaluate metabolic outcomes at the...
This federal Project Grant award of $256,504 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a clinical trial to evaluate novel shortened treatment regimens for isoniazid-monoresistant tuberculosis (IMR-TB). The trial aims to compare the time to sputum culture conversion, safety, and relapse-free cure rates between the standard 6-month treatment regimen and two 4-month intervention regimens....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,712 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to improve HIV testing among children under five in rural Uganda. The key objectives are to determine barriers and facilitators to pediatric HIV testing, and pilot a traditional healer-facilitated HIV testing intervention for children 18 months to 5 years old. UCSF will...
The Project Grant award R21AI182993 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a $187,998 research project to assess the carriage state of Mycobacterium tuberculosis (MTB), the primary agent of human tuberculosis (TB), in asymptomatic adults in Kampala, Uganda. The research hypothesis is that MTB possesses an upper respiratory tract (URT) carriage-like state in humans, similar to...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at understanding the early immune cell interactions that contribute to tuberculosis (TB) disease progression, particularly in the context of HIV co-infection. The primary awardee, The Washington University, will receive $899,894 over 5 years to: 1) Define the signaling effects of type I...
This federal Project Grant award, with ID R56AI180517, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $749,414 grant, awarded on August 1, 2024, supports research to understand the role of the macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and explore whether targeting MDR1 can shorten tuberculosis (TB) treatment duration. The key research aims...
This federal Project Grant award, valued at $766,877.00 and issued by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary goal is to determine if TDM can prevent premature discontinuation of linezolid, a critical medication for...
This $517,185 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to characterize the immune response to tuberculosis (TB) infection. The award will fund the integration of single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping across different stages of TB infection, including latent infection, recent infection, and...
This $1,297,775 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand the role of sirtuins, a type of protein, in regulating the interaction between tuberculosis (TB) and HIV infections in macrophages. The primary objectives are to: Analyze the impact of early TB and HIV infection on sirtuin gene and protein expression in macrophages, and develop an immunochemotherapy combining...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...